资讯

Altimmune: Pemvidutide Shows Promise In MASH, But Lacks Competitive Edge

Altimmune’s pemvidutide shows promise in MASH but lags on fibrosis vs. rivals. Learn what upcoming data means for ALT stock ...
Medindia56 分钟

U.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how ...

Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved INLEXZO™ (gemcitabine intravesical system), a new, potentially practice-changing approach for treating ...